Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A growing network of cancer-susceptibility genes.

Literature DB >> 12736286

A growing network of cancer-susceptibility genes.

Ashok R Venkitaraman¹.

Abstract

Mesh：

Substances：

Year: 2003 PMID： 12736286 DOI： 10.1056/NEJMcibr023150

Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245

Keyword Cloud
Cited

× No keyword cloud information.

17 in total

Review 1. PARP inhibitor treatment in ovarian and breast cancer.

Authors: Marcie K Weil; Alice P Chen
Journal: Curr Probl Cancer Date: 2011 Jan-Feb Impact factor: 3.187

Review 2. Susceptibility pathways in Fanconi's anemia and breast cancer.

Authors: Alan D D'Andrea
Journal: N Engl J Med Date: 2010-05-20 Impact factor: 91.245

3. Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.

Authors: Wael Jdey; Sylvain Thierry; Christophe Russo; Flavien Devun; Muthana Al Abo; Patricia Noguiez-Hellin; Jian-Sheng Sun; Emmanuel Barillot; Andrei Zinovyev; Inna Kuperstein; Yves Pommier; Marie Dutreix
Journal: Clin Cancer Res Date: 2016-08-24 Impact factor: 12.531

4. BRCTx is a novel, highly conserved RAD18-interacting protein.

Authors: David J Adams; Louise van der Weyden; Fanni V Gergely; Mark J Arends; Bee Ling Ng; David Tannahill; Roland Kanaar; Andrea Markus; Brian J Morris; Allan Bradley
Journal: Mol Cell Biol Date: 2005-01 Impact factor: 4.272

5. Fanconi anemia proteins are required to prevent accumulation of replication-associated DNA double-strand breaks.

Authors: Alexandra Sobeck; Stacie Stone; Vincenzo Costanzo; Bendert de Graaf; Tanja Reuter; Johan de Winter; Michael Wallisch; Yassmine Akkari; Susan Olson; Weidong Wang; Hans Joenje; Jan L Christian; Patrick J Lupardus; Karlene A Cimprich; Jean Gautier; Maureen E Hoatlin
Journal: Mol Cell Biol Date: 2006-01 Impact factor: 4.272

A growing network of cancer-susceptibility genes.

Review 1. PARP inhibitor treatment in ovarian and breast cancer.

Review 2. Susceptibility pathways in Fanconi's anemia and breast cancer.

3. Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.

4. BRCTx is a novel, highly conserved RAD18-interacting protein.

5. Fanconi anemia proteins are required to prevent accumulation of replication-associated DNA double-strand breaks.

6. Development of thymic lymphomas in mice disrupted of Brca2 allele in the thymus.

Review 7. PARP Inhibition in Cancer: An Update on Clinical Development.

8. Cancer initiation and progression: an unsimplifiable complexity.

9. Cancer: looking for simplicity and finding complexity.

Review 10. The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers.